Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

"This could be a huge step." Teen scientist makes stunning breakthrough that could slash costs of lifesaving drugs: 'I cannot ...

Local pharma stocks were rocky on Friday after President Donald Trump directed major drugmakers to reduce the cost of their ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Tarrytown-based Regeneron Pharmaceuticals has reported financial results for its second quarter of 2025. Net revenues increased 4% from the $3.54 ...

Second Quarter 2025 Results Key Financial Results Revenue: US$3.68b (up ...

If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...